Literature DB >> 28154086

Hyper-CVAD + epratuzumab as a salvage regimen for younger patients with relapsed/refractory CD22-positive precursor B-cell acute lymphocytic leukemia.

Patrice Chevallier1, Sylvain Chantepie2, Francoise Huguet3, Emmanuel Raffoux4, Xavier Thomas5, Thibaut Leguay6, Tony Marchand7, Francoise Isnard8, Aude Charbonnier9, Sébastien Maury10, Maria-Pilar Gallego-Hernanz11, Nelly Robillard12, Thierry Guillaume13, Pierre Peterlin13, Alice Garnier13, Fanny Rialland13, Claire Le Houerou13, David M Goldenberg14, William A Wegener14, Marie-C Béné12, Hervé Dombret4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28154086      PMCID： PMC5477620          DOI： 10.3324/haematol.2016.159905

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  14 in total

1.  (90)Y-labelled anti-CD22 epratuzumab tetraxetan in adults with refractory or relapsed CD22-positive B-cell acute lymphoblastic leukaemia: a phase 1 dose-escalation study.

Authors:  Patrice Chevallier; Thomas Eugene; Nelly Robillard; Françoise Isnard; Franck Nicolini; Martine Escoffre-Barbe; Françoise Huguet; Mathilde Hunault; Antoine Marcais; Joelle Gaschet; Michel Cherel; Thierry Guillaume; Jacques Delaunay; Pierre Peterlin; Marion Eveillard; Xavier Thomas; Norbert Ifrah; Simona Lapusan; Caroline Bodet-Milin; Jacques Barbet; Alain Faivre-Chauvet; Ludovic Ferrer; Marie C Bene; Claire Le Houerou; David M Goldenberg; William A Wegener; Françoise Kraeber-Bodéré
Journal:  Lancet Haematol       Date:  2015-02-25       Impact factor: 18.959

2.  Vincristine, dexamethasone and epratuzumab for older relapsed/refractory CD22+ B-acute lymphoblastic leukemia patients: a phase II study.

Authors:  Patrice Chevallier; Francoise Huguet; Emmanuel Raffoux; Anne Etienne; Thibaut Leguay; Francoise Isnard; Nelly Robillard; Thierry Guillaume; Jacques Delaunay; Aude Charbonnier; Arnaud Pigneux; Pierre Peterlin; Marie C Bené; William A Wegener; David M Goldenberg; Hervé Dombret
Journal:  Haematologica       Date:  2014-12-31       Impact factor: 9.941

3.  Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

Authors:  Elias Jabbour; Nicholas J Short; Jeffrey L Jorgensen; Musa Yilmaz; Farhad Ravandi; Sa A Wang; Deborah A Thomas; Joseph Khoury; Richard E Champlin; Issa Khouri; Partow Kebriaei; Susan M O'Brien; Guillermo Garcia-Manero; Jorge E Cortes; Koji Sasaki; Courtney D Dinardo; Tapan M Kadia; Nitin Jain; Marina Konopleva; Rebecca Garris; Hagop M Kantarjian
Journal:  Cancer       Date:  2016-09-07       Impact factor: 6.860

4.  International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia.

Authors:  Nicola Gökbuget; Hervè Dombret; Jose-Maria Ribera; Adele K Fielding; Anjali Advani; Renato Bassan; Victoria Chia; Michael Doubek; Sebastian Giebel; Dieter Hoelzer; Norbert Ifrah; Aaron Katz; Michael Kelsh; Giovanni Martinelli; Mireia Morgades; Susan O'Brien; Jacob M Rowe; Julia Stieglmaier; Martha Wadleigh; Hagop Kantarjian
Journal:  Haematologica       Date:  2016-09-01       Impact factor: 9.941

5.  How I treat adults with relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia.

Authors:  Noelle V Frey; Selina M Luger
Journal:  Blood       Date:  2015-05-12       Impact factor: 22.113

6.  The hyper-CVAD regimen improves outcome in relapsed acute lymphoblastic leukemia.

Authors:  C A Koller; H M Kantarjian; D Thomas; S O'Brien; M B Rios; S Kornblau; S Murphy; M Keating
Journal:  Leukemia       Date:  1997-12       Impact factor: 11.528

7.  Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia.

Authors:  Sébastien Maury; Sylvie Chevret; Xavier Thomas; Dominik Heim; Thibaut Leguay; Françoise Huguet; Patrice Chevallier; Mathilde Hunault; Nicolas Boissel; Martine Escoffre-Barbe; Urs Hess; Norbert Vey; Jean-Michel Pignon; Thorsten Braun; Jean-Pierre Marolleau; Jean-Yves Cahn; Yves Chalandon; Véronique Lhéritier; Kheira Beldjord; Marie C Béné; Norbert Ifrah; Hervé Dombret
Journal:  N Engl J Med       Date:  2016-09-15       Impact factor: 91.245

8.  SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia.

Authors:  Anjali S Advani; Shannon McDonough; Steven Coutre; Brent Wood; Jerald Radich; Martha Mims; Margaret O'Donnell; Stephanie Elkins; Michael Becker; Megan Othus; Frederick R Appelbaum
Journal:  Br J Haematol       Date:  2014-03-03       Impact factor: 6.998

9.  Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia.

Authors:  Hagop M Kantarjian; Daniel J DeAngelo; Matthias Stelljes; Giovanni Martinelli; Michaela Liedtke; Wendy Stock; Nicola Gökbuget; Susan O'Brien; Kongming Wang; Tao Wang; M Luisa Paccagnella; Barbara Sleight; Erik Vandendries; Anjali S Advani
Journal:  N Engl J Med       Date:  2016-06-12       Impact factor: 91.245

10.  A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias.

Authors:  J E Cortes; D-W Kim; J Pinilla-Ibarz; P le Coutre; R Paquette; C Chuah; F E Nicolini; J F Apperley; H J Khoury; M Talpaz; J DiPersio; D J DeAngelo; E Abruzzese; D Rea; M Baccarani; M C Müller; C Gambacorti-Passerini; S Wong; S Lustgarten; V M Rivera; T Clackson; C D Turner; F G Haluska; F Guilhot; M W Deininger; A Hochhaus; T Hughes; J M Goldman; N P Shah; H Kantarjian
Journal:  N Engl J Med       Date:  2013-11-01       Impact factor: 91.245
View more
  2 in total

Review 1.  The promise and perils of immunotherapy.

Authors:  Stefanie Lesch; Saar Gill
Journal:  Blood Adv       Date:  2021-09-28

Review 2.  Current Advances in Immunotherapy for Acute Leukemia: An Overview of Antibody, Chimeric Antigen Receptor, Immune Checkpoint, and Natural Killer.

Authors:  Yufeng Shang; Fuling Zhou
Journal:  Front Oncol       Date:  2019-09-19       Impact factor: 6.244
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.